TTNP Titan Pharmaceuticals Inc.

0.22
0  0%
Previous Close 0.22
Open 0.22
Price To Book 10.95
Market Cap 20,469,330
Shares 93,467,258
Volume 3,617,645
Short Ratio
Av. Daily Volume 12,799,614
Stock charts supplied by TradingView

NewsSee all news

  1. Titan Pharmaceuticals Reports Fourth Quarter And Full Year 2019 Financial Results

    SOUTH SAN FRANCISCO, Calif., March 30, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") today reported financial results for the fourth quarter and full year ended

  2. Titan Pharmaceuticals To Report Fourth Quarter And Full Year 2019 Financial Results On March 30, 2020

    SOUTH SAN FRANCISCO, Calif., March 26, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) today announced that its fourth quarter and full year 2019 financial results will be released after market close on

  3. Titan Pharmaceuticals Receives $5.9 Million From Exercise Of Warrants

    SOUTH SAN FRANCISCO, Calif., March 5, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) today announced that, since January 1, 2020, it has received proceeds of approximately $5.9 million as a result of the

  4. Titan Pharmaceuticals Announces Addition Of Probuphine® To Federal Supply Schedule

    SOUTH SAN FRANCISCO, Calif., Jan. 13, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) today announced that it has signed an agreement for Probuphine (buprenorphine) implant to be included on the Federal

  5. Titan Pharmaceuticals Announces Pricing of $2.2 Million Registered Direct Offering

    SOUTH SAN FRANCISCO, Calif., Jan. 7, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) today announced it has entered into a securities purchase agreement with certain accredited institutional investors to

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 treatment has commenced - noted October 11, 2017. DSMB recommended trial to continue - July 2, 2018 but further enrollment has been postponed due to lack of resources.
Ropinirole implant
Parkinson's disease
CRL issued April 30, 2013. Approved May 26 2016
Probuphine
Opioid dependence

Latest News

  1. Titan Pharmaceuticals Reports Fourth Quarter And Full Year 2019 Financial Results

    SOUTH SAN FRANCISCO, Calif., March 30, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") today reported financial results for the fourth quarter and full year ended

  2. Titan Pharmaceuticals To Report Fourth Quarter And Full Year 2019 Financial Results On March 30, 2020

    SOUTH SAN FRANCISCO, Calif., March 26, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) today announced that its fourth quarter and full year 2019 financial results will be released after market close on

  3. Titan Pharmaceuticals Receives $5.9 Million From Exercise Of Warrants

    SOUTH SAN FRANCISCO, Calif., March 5, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) today announced that, since January 1, 2020, it has received proceeds of approximately $5.9 million as a result of the

  4. Titan Pharmaceuticals Announces Addition Of Probuphine® To Federal Supply Schedule

    SOUTH SAN FRANCISCO, Calif., Jan. 13, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) today announced that it has signed an agreement for Probuphine (buprenorphine) implant to be included on the Federal

  5. Titan Pharmaceuticals Announces Pricing of $2.2 Million Registered Direct Offering

    SOUTH SAN FRANCISCO, Calif., Jan. 7, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) today announced it has entered into a securities purchase agreement with certain accredited institutional investors to

  6. Titan Pharmaceuticals Appoints Dr. Kate DeVarney To Its Board Of Directors

    SOUTH SAN FRANCISCO, Calif., Dec. 30, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) today announced that at its recent annual stockholders meeting, Kate DeVarney, Ph.D., its Executive Vice President and

  7. Titan Pharmaceuticals To Present At The First Annual BioTuesdays Pre-JPM Virtual Conference

    SOUTH SAN FRANCISCO, Calif., Dec. 3, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) today announced that management will present an update on the Company's business at the first annual BioTuesdays

  8. Kilmer Lucas Announces Agenda for BioTuesdays Pre-JPM Virtual Conference on December 10th

    CAMBRIDGE, ON / ACCESSWIRE / December 3, 2019 / Kilmer Lucas, a healthcare-focused investor relations and capital markets advisory firm, today announced the agenda for its first annual BioTuesdays Pre-JPM Virtual

  9. Titan Pharmaceuticals Reports Third Quarter 2019 Financial Results

    SOUTH SAN FRANCISCO, Calif., Nov. 14, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) today reported financial results for the third quarter ended September 30, 2019 and provided an update on its business.

  10. Titan Pharmaceuticals To Release Third Quarter 2019 Financial Results On November 14 - Conference Call To Follow

    SOUTH SAN FRANCISCO, Calif., Nov. 7, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) will announce its third quarter 2019 financial results after market close on Thursday, November 14, 2019.  Following the

  11. Titan Pharmaceuticals and Crossroads of Southern Nevada Announce Probuphine® Availability at Crossroads Rehabilitation Facilities

    SOUTH SAN FRANCISCO, Calif., Oct. 1, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) and Crossroads of Southern Nevada ("Crossroads") rehabilitation facility today announced that Crossroads has

  12. Titan Receives Approval For Second Year Of NIDA Grant Funding For Development Of A Nalmefene Implant

    SOUTH SAN FRANCISCO, Calif., Sept. 18, 2019 /PRNewswire/ -- National Institutes of Health's National Institute on Drug Abuse (NIDA) has approved approximately $6.1 million in second-year funding for Titan's